Xeris Biopharma Holdings, INC Form 4 insider transactions

Xeris Biopharma Holdings, Inc. Director Barbara-Jean Anne Bormann-Kennedy sold 15,000 shares of common stock for approximately $7.09 per share under a Rule 10b5-1 plan.

Xeris Biopharma Holdings, Inc.'s Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.0067 per share under a Rule 10b5-1 trading plan.

Xeris Biopharma Holdings, Inc. CEO and Director, John Patrick Shannon Jr., reported exercising stock options and selling common stock under a Rule 10b5-1 plan.

Xeris Biopharma's Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.3976 per share pursuant to a Rule 10b5-1 trading plan.

Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch disposed of 733 shares of common stock to cover tax liabilities from vested restricted stock units.

Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch's trust distributed 2,000 common shares to a beneficiary on September 11, 2025, with no sale occurring.

Xeris Biopharma Holdings Director Marla Persky sold 15,500 shares of common stock at a weighted average price of $7.7168 per share under a Rule 10b5-1 trading plan.

Xeris Biopharma Holdings, Inc. Director Jeffrey W. Sherman exercised stock options and subsequently sold a portion of the acquired shares.

Xeris Biopharma Director John Johnson sold 107,500 shares of common stock for approximately $7.32 per share.

Xeris Biopharma Director Dawn Halkuff sold 42,500 shares of common stock for approximately $309,000 on August 12, 2025, under a pre-planned Rule 10b5-1 program.

Xeris Biopharma CEO John Patrick Shannon Jr. disposed of 36,918 shares to cover tax obligations related to restricted stock unit vesting.

Xeris Biopharma's President and COO, Kevin McCulloch, reported routine stock transactions including shares withheld for taxes and an Employee Stock Purchase Plan acquisition.

Xeris Biopharma Holdings, Inc.'s President and Chief Operating Officer, Kevin McCulloch, has acquired 25,000 shares of common stock, signaling increased insider confidence in the company.

Xeris Biopharma Holdings, Inc. director Barbara-Jean Anne Bormann-Kennedy was granted 50,000 restricted stock units, increasing her beneficial ownership to 157,500 shares.

Xeris Biopharma Holdings, Inc. Director Marla Persky was granted 50,000 restricted stock units, aligning her interests with shareholders.

Xeris Biopharma Holdings, Inc. Director Dawn Halkuff was awarded 50,000 restricted stock units, aligning her interests with shareholders and increasing her beneficial ownership.

Xeris Biopharma Holdings, Inc. Director Jeffrey W. Sherman was granted 50,000 restricted stock units, vesting by June 2026, as disclosed in a recent SEC Form 4 filing.

Xeris Biopharma Holdings, Inc. Director John Johnson was granted 50,000 restricted stock units, aligning his interests with shareholders and vesting by June 2026.

Xeris Biopharma Holdings, Inc. Director Garheng Kong was granted 50,000 shares of common stock through a restricted stock unit award, increasing his total beneficial ownership to 214,144 shares.

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, reports a transaction involving common stock due to tax obligations related to vested restricted stock units.

Director James Aloysius Brady acquired 100,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award.

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, sold 40,000 shares of common stock at an average price of $5.4311 on March 20, 2025.

Xeris Biopharma's President and COO, Kevin McCulloch, reports the acquisition and disposal of company stock and stock appreciation rights.

CEO John Patrick Shannon Jr. reports acquisition of shares and stock appreciation rights in Xeris Biopharma Holdings.

Xeris Biopharma's Chief Legal Officer, Beth Hecht, reports the acquisition and disposal of company stock and stock appreciation rights.

Xeris Biopharma's Chief Financial Officer, Steven Pieper, engaged in stock transactions including the vesting of restricted stock units, tax withholdings, and the grant of stock appreciation rights.

Xeris Biopharma's Senior Vice President, Kenneth Johnson, sold shares to cover tax obligations related to vested restricted stock units.

John Patrick Shannon Jr., CEO of Xeris Biopharma Holdings, disposed of shares to cover income tax obligations related to vested Restricted Stock Units.

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, disposed of shares to cover income tax obligations related to vested Restricted Stock Units.

Kenneth Erland Johnson, a Senior Vice President at Xeris Biopharma Holdings, disposed of shares to cover income tax obligations related to vested Restricted Stock Units.